Last update Aug. 30, 2021
Plerixafor is a selective CXCR4 chemokine receptor antagonist. It causes leukocytosis and elevated levels of hematopoietic progenitor cells.
Indicated, in combination with a granulocyte colony stimulating factor, to enhance the mobilization of hematopoietic stem cells into peripheral blood for their collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma.
Authorized use in patients from one year of age.
Daily subcutaneous administration for 2 to 4 and up to 7 days.
At the date of the last update, there was no available published data on its excretion in breast milk.
Its pharmacokinetic data (large volume of distribution and moderately high molecular weight) make it unlikely to pass into breast milk in a clinically significant amount.
Its null oral bioavailability (Pettersson 2008, Rosenkilde 2007 and 2004) prevents the passage to plasma of the infant from ingested breast milk, except perhaps in the premature and during the immediate neonatal period during which there may be greater intestinal permeability.
Its possible frequent side effects (mainly gastrointestinal) are not serious and should be monitored for in the infant.
We do not have alternatives for Plerixafor.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM